ALK-Abelló Full Year 2024 Earnings: EPS Misses Expectations

ALK-Abelló (CPH:ALK B) Full Year 2024 Results

Key Financial Results

• Revenue: kr.5.54b (up 15% from FY 2023).
• Net income: kr.815.0m (up 68% from FY 2023).
• Profit margin: 15% (up from 10% in FY 2023). The increase in margin was driven by higher revenue.
• EPS: kr.3.68 (up from kr.2.20 in FY 2023).

ALK B Products In Clinical Trials

• Phase II: 2.
• Phase III: 3.

ALK B Post-Clinical Trial Products

• Pre-registration: 3.

All figures shown in the chart above are for the trailing 12 month (TTM) period

ALK-Abelló EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 3.9%.

The primary driver behind last 12 months revenue was the Other Europe segment contributing a total revenue of kr.1.45b (26% of total revenue). The largest operating expense was Sales & Marketing costs, amounting to kr.1.56b (57% of total expenses). Explore how ALK B's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Pharmaceuticals industry in Europe.

Performance of the market in Denmark.

The company's shares are down 2.0% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. See our latest analysis on ALK-Abelló's balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.